For years, the narrative surrounding classic psychedelics—specifically psilocybin—has been one of clinical salvation. Headlines have promised a...
Chemotherapy and Targeted Therapy
In the high-stakes arena of pharmaceutical development, the “see-saw” effect is a standard law of gravity. When...
In one of the most significant venture capital infusions of the year, ophthalmology-focused startup Ollin Biosciences has...
By Jonathan Gardner | Published June 23, 2026 In a decisive move to bolster domestic biopharmaceutical competitiveness,...
In 2020, the biotechnology sector witnessed a seismic shift when Bristol Myers Squibb (BMS) executed a $13...
By Delilah Alvarado | June 23, 2026 Pfizer’s strategic pivot toward becoming a global powerhouse in oncology...
After years of pandemic-induced volatility and a prolonged era of declining research and development (R&D) productivity, the...
Imagine managing a multi-billion-dollar clinical research project involving nearly six million individual data points. You have at...
In a landmark deal that signals a shifting tide in the biotech sector, the startup Cellular Intelligence...
In the modern era of medicine, the therapeutic success of a breakthrough drug is no longer determined...
